Morgan Stanley resumed coverage on Thermo Fisher with a new price target
$TMO
Industrial Machinery/Components
Industrials
Morgan Stanley resumed coverage of Thermo Fisher with a rating of Overweight and set a new price target of $670.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2025 | $660.00 | Neutral → Buy | Citigroup |
| 12/9/2025 | $685.00 | Buy | Goldman |
| 12/8/2025 | $750.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 12/2/2025 | $670.00 | Overweight | Morgan Stanley |
| 12/1/2025 | $670.00 | Hold → Buy | HSBC Securities |
| 9/11/2025 | $550.00 | Equal Weight → Overweight | Barclays |
| 8/19/2025 | Outperform | William Blair | |
| 7/24/2025 | $510.00 | Buy → Hold | HSBC Securities |
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence (AI) platform and Thermo Fisher Scientific solutions to progressively increase the automation, accuracy and speed of laboratories. The companies are working together to evolve the digital foundation that powers scientific instruments, laboratory infrastructure and data -- connecting them to powerful AI solutions, helping scientists reduce manual steps and accelerate scientific advancement. Accelerating smarter, connected scientific workflows
Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section of our website, www.thermofisher.com, with a replay accessible shortly after the presentation concludes. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our custome
Citigroup upgraded Thermo Fisher from Neutral to Buy and set a new price target of $660.00
Goldman initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $685.00
KeyBanc Capital Markets upgraded Thermo Fisher from Sector Weight to Overweight and set a new price target of $750.00
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
CERT - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
144 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2025 before the market opens on Thursday, January 29, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the "Investors" section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 054943. The earnings press release and related information can also be fo
OlivePoint Capital ("OlivePoint"), an institutional real estate investment manager focused on thematic and special situations strategies, and Redwood Capital Management, LLC, a global alternative investment manager focused on opportunistic credit and other special situation investments ("Redwood Capital"), today announced its acquisition of 3900 Paramount Parkway, a 220,000-square-foot Class A office building located within Research Triangle Park (RTP) in Raleigh–Durham, one of the fastest-growing innovation hubs in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215054691/en/3900 Paramount Parkway - Raleigh,
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on January 15, 2026, to shareholders of record as of December 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the dev
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)